Clinical trial Archives

News and Trends 16 Feb 2023

Bladder cancer investigational therapy may be given at home

UroGen Pharma Ltd. has announced preliminary results of a study to assess the feasibility of home instillation of UGN-102 (mitomycin) for intravesical solution, an investigational therapy in development for primary chemoablation of low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). In the study, UGN-102 was suitable to administer at home by a visiting nurse under the […]

February 16, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Cytovation melanoma study under way

Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

IMV presents positive lymphoma trial results

IMV Inc. has announced positive preliminary data from its VITALIZE phase 2B trial. The study is evaluating IMV Inc. lead DPX product, maveropepimut-S (MVP-S), in combination with pembrolizumab, in patients with relapsed, refractory diffuse large B cell lymphoma (r/r DLBCL). IMV Inc. is a biopharmaceutical company developing a portfolio of immune-educating therapies based on its […]

February 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Minoryx Therapeutics announces X-linked adrenoleukodystrophy data

Minoryx Therapeutics has announced that data from its phase 2/3 ADVANCE clinical trial of lead candidate, leriglitazone, has been published in The Lancet Neurology. The trial, assessing the efficacy and safety of leriglitazone in male patients with adrenomyeloneuropathy, is the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients. X-linked adrenoleukodystrophy (X-ALD) […]

February 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Janssen reports positive topline phase 2 HDFN results

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the proof-of-concept phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition that can cause life-threatening anemia in the […]

February 10, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study

Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […]

February 10, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

Sometimes, there’s an interview that we do that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

Opinion 9 Feb 2023

How AI and ML can transform clinical research

By Gary Shorter, head of artificial intelligence at IQVIA Clinical trials are currently in an era of transformation through digitization, with much of the change being attributed to the integration of technologies such as natural language processing (NLP), artificial intelligence (AI), and machine learning (ML). Like many industries, health and life sciences are experiencing rapid […]

February 9, 2023 - 4 minutesmins - By External Contributor

News and Trends 9 Feb 2023

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death. Nosocomial pathogen methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely-used antibiotics. Infections with MRSA are harder to treat and […]

February 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Cleveland Clinic breast cancer vaccine study moves forward

Researchers from global health system Cleveland Clinic have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Funded by the U.S. Department of Defense, the new phase 1b study will enroll cancer-free individuals at high risk for developing […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Certa scleroderma study shows improvement in more than 60% of patients

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently completed a global phase 2, multi-centre, randomized, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in patients with scleroderma. […]

February 7, 2023 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Bladder cancer investigational therapy may be given at home

Cytovation melanoma study under way

IMV presents positive lymphoma trial results

Minoryx Therapeutics announces X-linked adrenoleukodystrophy data

Janssen reports positive topline phase 2 HDFN results

Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study

Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

How AI and ML can transform clinical research

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

First toxic shock syndrome vaccine phase 2 study completed

Cleveland Clinic breast cancer vaccine study moves forward

Certa scleroderma study shows improvement in more than 60% of patients

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!